Last reviewed · How we verify
Progesteron
At a glance
| Generic name | Progesteron |
|---|---|
| Sponsor | Minia University |
| Target | Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Amenorrhea Secondary to Ovarian Dysfunction
- Atrophic vaginitis
- Contraception
- Corpus Luteum Insufficiency Syndrome
- Dysfunctional uterine bleeding
- Endometrial Hyperplasia Prevention
- Endometrial carcinoma
- Endometriosis
- Infertility Secondary to Progesterone Deficiency
- Menopausal flushing
- Postmenopausal osteoporosis
- Prevention of Premature Labor
- Secondary malignant neoplasm of kidney
- Secondary physiologic amenorrhea
Common side effects
- Nausea
- Fatigue
- Vaginal mycosis
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Dizziness
- Breast tenderness
- Abdominal distension
- Acne
- Dysmenorrhea
- Mood swing
Serious adverse events
- Endometrial carcinoma
- Hepatic failure
- Hepatic necrosis
- Circulatory collapse
- Loss of consciousness
- Anaphylactic reaction
- Suicidal ideation
- Transient ischemic attack
- Convulsion
- Spontaneous abortion
Key clinical trials
- Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. (PHASE4)
- Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (NA)
- Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency (PHASE3)
- Luteal Support in Artificial Vitrified/Warmed Cycles With Low Progesterone (PHASE3)
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients (NA)
- First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency (PHASE1)
- Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Progesteron CI brief — competitive landscape report
- Progesteron updates RSS · CI watch RSS
- Minia University portfolio CI